Safety issues of psilocybin and LSD as potential rapid acting antidepressants and potential challenges
Giordano Novak Rossi, Jaime E. C. Hallak, José Carlos Bouso Saiz, Rafael G. Dos Santos
Expert Opinion on Drug Safety April 15, 2022 DOI: 10.1080/14740338.2022.2066650 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Randomized Peer reviewed |
|---|---|
| Interventions | Psilocybin LSD |
| Topics | Anxiety Psilocybin LSD |
| Keywords | Tolerability Adverse effect Context archaeology Pharmacology Clinical trial Randomized controlled trial Antidepressant Placebo Hallucinogen Alternative medicine Pathology |
| Citations | 24 |
| Key findings | No serious adverse events were related to psilocybin or LSD, but concerns about dissociation, paranoia, and confusion remain, warranting larger trials. |
Abstract
There were no serious AEs related to psilocybin and LSD administration. Most AEs were expected, manageable, and transient. Nevertheless, safety and tolerability concerns regarding some effects, such as dissociation, paranoia, and confusion, remain. Thus, randomized controlled trials with bigger samples are warranted to confirm their therapeutic effects and further investigate their safety and tolerability.